Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 6Venous Thrombosis 5Venous Thromboembolism 2Pulmonary Embolism 2Thrombosis 1Thromboembolism 1Hemostatic Disorders 1

Interventions

Dalteparin 4Saline Solution 3Gemcitabine 3Enoxaparin 3Warfarin 2Tinzaparin 2Heparin, Low-Molecular-Weight 2Fondaparinux 2Aspirin 2130-nm albumin-bound paclitaxel 2palbociclib 1isoquercitrin 1enoxaparin sodium 1edoxaban 1apixaban 1alvocidib 1Tranexamic Acid 1Sodium Chloride 1Sodium Bicarbonate 1Rivaroxaban 1Pentetic Acid 1PEGPH20 1Nadroparin 1Minocycline 1Ketoconazole 1Heparin 1Fluorodeoxyglucose F18 1Fluoridation 1Estramustine 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thromboembolism × edoxaban × Clear all
NCT04072068 2023-05-30

EDOI

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 4 Completed
150 enrolled

Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡